ClinicalTrials.gg
Not yet recruitingNCT07941141Updated Nov 17, 2026

Visc-Buckle Trial 1

A Phase 1/2 interventional study of Minimally-invasive suprachoroidal buckle in Retinal Detachment Rhegmatogenous, sponsored by Sunnybrook Health Sciences Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sunnybrook Health Sciences Centre · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Retinal Detachment with a site in Canada — 4 open to participants now, 4 under way, none of them phase 3. Retinal Detachment · Canada.

Planned enrollment
11th of 12
13 · median 80
Started
2026
with 1 other
Phase 1/2
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
2 of 13
Sunnybrook Health Sciences Centre

Among the 13 studies in Retinal Detachment with a site in Canada, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 13th registered.

Retinal Detachment

200 studies on the registry are indexed under Retinal Detachment; 30 are open to participants now.

Browse Retinal Detachment studies →

Open to participants now

4 of the 13 studies in Retinal Detachment with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 21 Retinal Detachment studies recruiting now, 15 (71%) set no upper age limit and 4 (19%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Retinal Detachment with a site in Canada, or all of them as a file.
02

Study summary

A retinal detachment is a vision-threatening condition that most often requires surgical treatment. Retinal detachments occur because a tear or hole forms in the retina through which liquid can penetrate beneath the retina, separating it from its normal position. Though current surgical treatments for retinal detachment are effective, they all have downsides, such as the need for uncomfortable head positioning after surgery, and slow recovery of vision. In this study, the investigators will test a new treatment for retinal detachment. The investigators will use a special needle to inject a gel between the layers of the eye wall to block off the breaks in the retina and heal the detachment. This procedure combines and modifies ideas from existing surgical techniques, but will eventually be less risky and have fewer disadvantages than current treatments.

03

Conditions studied

  • Retinal Detachment Rhegmatogenous

Browse trials for

Keywords

  • Suprachoroidal Buckle
  • Hydrogel Buckle
  • Suprachoroidal Viscopexy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Rhegmatogenous retinal detachment with single retinal break, or group of breaks within 1 clock hour of one another, located in the inferior 4 clock hours;
  • Retinal break(s) anterior to the equator of the globe;
  • Macula detached;
  • Ocular media judged to be sufficiently clear for adequate examination and laser retinopexy;
  • Age 18 years or older; and
  • Participant is capable of signing or has an acceptable substitute decision maker capable of signing the informed consent form on their behalf. A responsible parent or caregiver of an assenting minor must agree with the minor's decision to participate.

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years;
  • History of prior ocular surgery in the study eye, excluding laser refractive surgery, uncomplicated cataract surgery and pneumatic retinopexy;
  • History of active uveitis or uncontrolled glaucoma (IOP > 35) in the last 3 months;
  • Presence of proliferative vitreoretinopathy Grade C or higher;
  • Presence of choroidal detachment on baseline clinical examination or B-scan ultrasound
  • Has a medical condition requiring use of anti-coagulant medication
  • Patient or caregiver unable to provide ;
  • Patient unwilling to return for research follow-up visits; or
  • Known allergy to nickel or ocular viscoelastic device.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (estimated)

Study arms

  • Experimental
    Minimally-invasive suprachoroidal buckle

    Patients will be treated with an investigational surgical procedure for retinal detachment repair. The procedure is a minimally-invasive modification of an established procedure called "suprachoroidal buckling".

    Procedure: Minimally-invasive suprachoroidal buckle

Interventions

  • ProcedureMinimally-invasive suprachoroidal buckle

    An investigational suprachoroidal space injector (Everads Therapy) will be used to inject a bleb of commercially-available ophthalmic viscoelastic (sodium hyaluronate 2.3%; aka Healon 5) into the suprachoroidal space to create a temporary intraocular buckling effect under the causative retinal break(s).

    Also known as: Visc-Buckle

06

What researchers measure

Primary outcomes

  1. Intra-operative and post-operative adverse events (Safety)

    Intra-operative and post-operative adverse events will be measured and categorized using the Terminologies for Categorized Adverse Event Reporting recommended by the International Medical Device Regulators Forum (IMDRF). The following will be considered adverse events of special interest: * Inability to achieve suprachoroidal bleb intra-operatively * Intraocular hemorrhage (sub-retinal, suprachoroidal, or intravitreal) * Loss of vision * Sub-retinal injection of viscoelastic * Iatrogenic retinal tear * Elevated intraocular pressure (\>10 mmHg higher than baseline and absolute value \>30mmHg) * Significant intraocular inflammation (\>2+ anterior chamber cell or vitreous haze, or retinitis, choroiditis or scleritis) * Endophthalmitis * Ocular pain

    Time frame: 12 weeks

Secondary outcomes

  1. Single operation retinal reattachment rate (in percentage) at post-op week 4 and 12

    Efficacy

    Time frame: 12 weeks

  2. Time to complete retinal reattachment in days

    Efficacy

    Time frame: 12 weeks

  3. Change from baseline visual acuity at post-op weeks 4 and 12 (in letters)

    Efficacy

    Time frame: 12 weeks

  4. Time until buckling effect is no longer visible (in days)

    Efficacy

    Time frame: 12 weeks

  5. morphopsia score at post-op weeks 4 and 12 (in M-chart score)

    Efficacy

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Muni RH, Melo IM, Pecaku A, Mannina A, Batawi H, Bansal A. In-Office Suprachoroidal Viscopexy for Rhegmatogenous Retinal Detachment Repair. JAMA Ophthalmol. 2023 Oct 1;141(10):933-936. doi: 10.1001/jamaophthalmol.2023.3785. PubMed 37615957 ↗
  • Szurman P, Boden K, Januschowski K. Suprachoroidal Hydrogel Buckling as a Surgical Treatment of Retinal Detachment: Biocompatibility and First Experiences. Retina. 2016 Sep;36(9):1786-90. doi: 10.1097/IAE.0000000000001116. No abstract available. PubMed 27429389 ↗
  • Barak Y, Rotenstreich Y, Mano Tamir K, Adakhovska A, Mangelus M, Hoggeg AB. A Novel Suprachoroidal Delivery Technology: Results from a First-in-Human Pilot Study. In: Proceedings of the Euretina Congress; 2024 September 19-22; Barcelona. Available from: https://abstracts.euretina.org/2024/lb24-157-3858/r/rec5jxj51GsymuUJY
  • Rotenstreich Y, Sher I, Lawrence M, Mangelus M, Ingerman A, Barak Y. A Novel Device for Suprachoroidal Drug Delivery to Retina: Evaluation in Nonhuman Primates. Transl Vis Sci Technol. 2023 Jun 1;12(6):3. doi: 10.1167/tvst.12.6.3. PubMed 37289173 ↗
  • Mikhail M, El-Rayes EN, Kojima K, Ajlan R, Rezende F. Catheter-guided suprachoroidal buckling of rhegmatogenous retinal detachments secondary to peripheral retinal breaks. Graefes Arch Clin Exp Ophthalmol. 2017 Jan;255(1):17-23. doi: 10.1007/s00417-016-3530-8. Epub 2016 Nov 16. PubMed 27853956 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 17, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941141
Collaborators
Everads Therapy
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Kenneth Eng, MD, FRCSC
Contact
Kenneth.Eng@sunnybrook.ca
416-480-4688
Gareth Mercer, MD, PhD
Contact
Gareth.Mercer@sunnybrook.ca
Kenneth Eng, MD FRCSC
principal investigator · Sunnybrook Health Sciences Centre, Department of Ophthalmology and Vision Science
Peter Kertes, MD FRCSC
principal investigator · Sunnybrook Health Sciences Centre, Department of Ophthalmology and Vision Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion